Capstan Medical garners $110M for robotic-enabled heart valve repair tech

The funding comes more than a year after the company closed an oversubscribed $31.4 million Series B round.
By Jessica Hagen
11:43 am
Share

Photo: Morsa Images/Getty Images

California-based Capstan Medical, maker of robotic-enabled tools for heart valve disease, closed an oversubscribed $110 million Series C round led by Eclipse. 

Existing investors Intuitive Ventures, Yu Galaxy, and new investor Gideon Strategic Partners, participated in the round. 

WHAT IT DOES

The company offers surgical robotics with catheter-based technology and implants to repair and replace heart valves. It will use the funds to advance its reach within healthcare.

"Percutaneous intervention has the opportunity to dramatically increase the treatment options for the millions of people suffering from heart valve disease. At Capstan, we believe that our robotic platform with a full portfolio of implants can uniquely address the urgent needs of this underserved patient population," Maggie Nixon, CEO of Capstan Medical, said in a statement. "We have pulled together the right people at the right time to make this happen and are energized by the incredible support of our investors." 

MARKET SNAPSHOT

Last year, Capstan closed an oversubscribed $31.4 million Series B funding round, which Eclipse also led. 

According to the American Heart Association, heart disease is the leading cause of death in the U.S., and has been for more than 100 years. Yet, more than half (51%) of 6,077 adults (aged 18 and over) surveyed in a 2023 Harris Poll survey were unaware of the statistics.

Other companies focused on cardiovascular health include Story Health, which offers telehealth, health coaches, AI and connected devices to provide patients with continuous specialty care for heart-related and other chronic conditions. 

Digital cardiac and lung disease health startup Eko Health received FDA 510(k) clearance for its AI-enabled cardiac tool that helps with the early detection of low ejection fraction, a key indicator of heart failure.    

Tech-enabled heart disease detection company CardioSignal, cardiology-care platform CardioOne and Moray Medical, the U.S.-based developer of the Coral interventional robotics platform, are also players in the space.

Share